First-in-class therapeutics against ocular diseases
Revolutionizing severe retinal disease care with non-invasive topical therapies
Saving lives with groundbreaking treatments for uveal melanoma
A united team dedicated to bringing novel therapies in focus for patients
Roca Therapeutics, a Landmark BioVentures Company
Bringing new visions to life for patients
Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision to life.
About Us
Roca Therapeutics’ team is comprised of international industry and top notch research experts in VEGF-independent mechanisms of angiogenesis and inflammation, and in the development of new therapies based on first-in-class small molecules.
Learn more about RCT002 for retinopathies
RCT002 is developed for topical administration to treat Radiation-induced maculopathy and other severe ocular diseases. RCT002 modifies disease by blocking resistant angiogenesis, oxidative stress, inflammation, and fibrosis.